![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ALG1 |
Gene summary for ALG1 |
![]() |
Gene information | Species | Human | Gene symbol | ALG1 | Gene ID | 56052 |
Gene name | ALG1 chitobiosyldiphosphodolichol beta-mannosyltransferase | |
Gene Alias | CDG1K | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9BT22 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56052 | ALG1 | LZE4T | Human | Esophagus | ESCC | 5.33e-13 | 2.07e-01 | 0.0811 |
56052 | ALG1 | LZE8T | Human | Esophagus | ESCC | 2.63e-03 | 7.52e-02 | 0.067 |
56052 | ALG1 | LZE20T | Human | Esophagus | ESCC | 7.82e-04 | 1.30e-01 | 0.0662 |
56052 | ALG1 | LZE22D1 | Human | Esophagus | HGIN | 2.92e-02 | 1.47e-01 | 0.0595 |
56052 | ALG1 | LZE22T | Human | Esophagus | ESCC | 2.96e-03 | 2.74e-01 | 0.068 |
56052 | ALG1 | LZE24T | Human | Esophagus | ESCC | 1.66e-10 | 3.14e-01 | 0.0596 |
56052 | ALG1 | P1T-E | Human | Esophagus | ESCC | 4.14e-06 | 1.69e-01 | 0.0875 |
56052 | ALG1 | P2T-E | Human | Esophagus | ESCC | 7.82e-27 | 5.16e-01 | 0.1177 |
56052 | ALG1 | P4T-E | Human | Esophagus | ESCC | 1.36e-10 | 2.39e-01 | 0.1323 |
56052 | ALG1 | P5T-E | Human | Esophagus | ESCC | 1.43e-13 | 2.21e-01 | 0.1327 |
56052 | ALG1 | P8T-E | Human | Esophagus | ESCC | 1.19e-15 | 2.41e-01 | 0.0889 |
56052 | ALG1 | P9T-E | Human | Esophagus | ESCC | 4.89e-09 | 8.05e-02 | 0.1131 |
56052 | ALG1 | P10T-E | Human | Esophagus | ESCC | 5.49e-14 | 1.27e-01 | 0.116 |
56052 | ALG1 | P11T-E | Human | Esophagus | ESCC | 3.17e-05 | 2.60e-01 | 0.1426 |
56052 | ALG1 | P12T-E | Human | Esophagus | ESCC | 2.86e-31 | 4.03e-01 | 0.1122 |
56052 | ALG1 | P15T-E | Human | Esophagus | ESCC | 8.17e-18 | 3.27e-01 | 0.1149 |
56052 | ALG1 | P16T-E | Human | Esophagus | ESCC | 3.41e-20 | 2.10e-01 | 0.1153 |
56052 | ALG1 | P17T-E | Human | Esophagus | ESCC | 1.30e-10 | 3.38e-01 | 0.1278 |
56052 | ALG1 | P19T-E | Human | Esophagus | ESCC | 2.08e-04 | 2.16e-01 | 0.1662 |
56052 | ALG1 | P20T-E | Human | Esophagus | ESCC | 1.12e-16 | 2.62e-01 | 0.1124 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
GO:0006490 | Oral cavity | OSCC | oligosaccharide-lipid intermediate biosynthetic process | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
GO:000645719 | Oral cavity | LP | protein folding | 125/4623 | 212/18723 | 1.62e-26 | 8.45e-24 | 125 |
GO:000648713 | Oral cavity | LP | protein N-linked glycosylation | 35/4623 | 65/18723 | 4.33e-07 | 1.22e-05 | 35 |
GO:00064881 | Oral cavity | LP | dolichol-linked oligosaccharide biosynthetic process | 12/4623 | 18/18723 | 2.02e-04 | 2.20e-03 | 12 |
GO:00064901 | Oral cavity | LP | oligosaccharide-lipid intermediate biosynthetic process | 12/4623 | 19/18723 | 4.25e-04 | 4.08e-03 | 12 |
GO:007008511 | Oral cavity | LP | glycosylation | 77/4623 | 240/18723 | 5.60e-03 | 3.38e-02 | 77 |
GO:000648611 | Oral cavity | LP | protein glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
GO:004341311 | Oral cavity | LP | macromolecule glycosylation | 73/4623 | 226/18723 | 5.72e-03 | 3.44e-02 | 73 |
GO:00064877 | Skin | cSCC | protein N-linked glycosylation | 33/4864 | 65/18723 | 1.63e-05 | 1.99e-04 | 33 |
GO:00064883 | Skin | cSCC | dolichol-linked oligosaccharide biosynthetic process | 10/4864 | 18/18723 | 7.25e-03 | 3.44e-02 | 10 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005106 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
hsa0051013 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG1 | SNV | Missense_Mutation | c.252N>T | p.Gln84His | p.Q84H | Q9BT22 | protein_coding | tolerated(0.27) | benign(0) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ALG1 | SNV | Missense_Mutation | novel | c.276G>T | p.Gln92His | p.Q92H | Q9BT22 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALG1 | SNV | Missense_Mutation | rs150272167 | c.946G>A | p.Val316Ile | p.V316I | Q9BT22 | protein_coding | tolerated(0.36) | benign(0.144) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALG1 | SNV | Missense_Mutation | c.1387G>A | p.Asp463Asn | p.D463N | Q9BT22 | protein_coding | tolerated(0.16) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
ALG1 | SNV | Missense_Mutation | c.485N>A | p.Ser162Tyr | p.S162Y | Q9BT22 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ALG1 | SNV | Missense_Mutation | rs145317306 | c.787C>T | p.Arg263Trp | p.R263W | Q9BT22 | protein_coding | tolerated(0.19) | benign(0.005) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD |
ALG1 | SNV | Missense_Mutation | c.481N>C | p.Tyr161His | p.Y161H | Q9BT22 | protein_coding | tolerated(0.15) | probably_damaging(0.994) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ALG1 | SNV | Missense_Mutation | c.806N>C | p.Leu269Pro | p.L269P | Q9BT22 | protein_coding | tolerated(0.25) | benign(0.124) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
ALG1 | SNV | Missense_Mutation | rs143906919 | c.764N>T | p.Thr255Met | p.T255M | Q9BT22 | protein_coding | tolerated(0.27) | benign(0.005) | TCGA-QG-A5Z2-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ALG1 | deletion | Frame_Shift_Del | c.398delC | p.Pro133GlnfsTer59 | p.P133Qfs*59 | Q9BT22 | protein_coding | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |